Targeting the CXCL12/CXCR4 pathway by an optimized derivative or EPI-X4 preserves chondrocyte function and offers a novel therapeutic approach in rheumatic diseases
These findings suggest that EPI-X4 JM#21 may represent potential alternative to AMD3100 for targeting the CXCL12/CXCR4 pathway in OA, warranting further in vivo validation.
Authors
- Mirja Harms (ORCID: https://orcid.org/0000-0002-5460-5166)
- Jan Münch (ORCID: https://orcid.org/0000-0001-7316-7141)
- Leonie Ruths
- Felix Haußner
- Tobias Freitag (ORCID: https://orcid.org/0000-0001-5971-2991)
- Sonja‐Verena Albers (ORCID: https://orcid.org/0000-0003-2459-2226)
- Jana Riegger (ORCID: https://orcid.org/0000-0003-0048-5047)
- Hannah de Hesselle
Institutions
- Universität Ulm (DE)
- University Hospital Ulm (DE)
- Technische Hochschule Ulm (DE)
Publication Details
- Journal
- Arthritis Research & Therapy
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1186/s13075-025-03691-9
- Citations
- 1
- Primary Topic
- Chemokine receptors and signaling
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Baden-Württemberg Stiftung
- Deutsche Forschungsgemeinschaft
- Universität Ulm